Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

Published:2013-03-07 Issue:5 Volume:88 Page:350-354
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Cortes J.¹,Digumarti R.²,Parikh P.M.³,Wetzler M.⁴,Lipton J.H.⁵,Hochhaus A.⁶,Craig A.R.⁷,Benichou A.-C.⁷,Nicolini F.E.⁸,Kantarjian H.M.¹,

Affiliation:

1. Department of Leukemia; UT MD Anderson Cancer Center; Houston; Texas

2. Medical Oncology, Nizam's Institute of Medical Sciences; Hyderabad; India

3. Indian Cooperative Oncology Network; Mumbai; India

4. Division of Leukemia, Roswell Park Cancer Institute; Buffalo; New York

5. Chronic Myelogenous Leukemia Group, Department of Hematology/Medical Oncology, Princess Margaret Hospital; Toronto; Ontario; Canada

6. Abteilung Hðmatologie/Onkologie, Klinik für Innere Medizin II; Universitätsklinikum Jena; Jena; Germany

7. Formerly of ChemGenex Pharmaceuticals; an indirect wholly owned subsidiary of Teva Pharmaceuticals; Petach Tikva; Israel

8. Hematologie Clinique, Centre Hospitalier Lyon Sud; Pierre Bénite; France

Publisher

Wiley

Subject

Hematology

Reference20 articles.

1. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia,2009

2. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results;Kantarjian;Blood,2011

3. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib;Shah;Haematologica,2010

4. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up;Garg;Blood,2009

5. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy;Giles;Leukemia,2010

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review;Therapeutic Advances in Hematology;2023-01

2. Natural STAT3 inhibitors: A mini perspective;Bioorganic Chemistry;2021-10

3. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance;Cancers;2021-09-26

4. Natural products as drugs and tools for influencing core processes of eukaryotic mRNA translation;Pharmacological Research;2021-08

5. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma;JCI Insight;2021-06-22